Blue chip

[Francesco Massari @fmassari79]

The revolution in the treatment of mRCC goes on !!
#GU21

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#GU21 @ASCO Cabozantinib + Belzutifan (HIF-2a inhibitor) combination is well tolerated and shows very promising efficacy~88% pts of mRCC #kidneycancer in pre-treated patients @DrChoueiri @OncoAlert @urotoday @montypal

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#GU21 @ASCO King from @cityofhope is here with a bang👏👏 Establishes Cabozantinib as standard of care in metastatic papillary RCC #kidneycancer in this @SWOG1500 trial which just published in @TheLancet 👇@oncoalert @PrimoLaraMD @urotoday @DrChoueiri @DrRaviSalgia @VivekSubbiah

[Brian Rini, MD @brian_rini]

Updated RCC IO Combo Table with CLEAR data after presentation today at #ASCOGU21 . @Uromigos podcast to discuss IO/TKI landscape coming soon!

[Immunovia @immunovia]

Immunovia On Track For IMMray™ PanCan-d Sales Start In Q1 2021. For complete press release:
https://t.co/LseNlf2iHJ

[Daniel Castellano @cdanicas]

📌.- CLEAR phase 3 study: LEN+ PEMBRO a new 1L option for #mRCC. Impressive results 🙌 with significant longer OS vs SUN (HR 0.66) and ORR 71% (CR 16%). Pending IMDC risk-group analysis! #GU21 @ASCO 👇👇

[Immunovia @immunovia]

Chief Executive Officer, Patrik Dahlen Buys Immunovia Warrants. For complete press release: https://t.co/8d2jg6Yd4n

[Blue chip @b1u3chip]

2020 Top Stories in Renal Cell Carcinoma: Management of Renal Cell Carcinoma: Overview of Changes in the Past Decade | PracticeUpdate https://t.co/K2g0JEPlko

[Pharmacutical Daily @PharmacDaily]

Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC) https://t.co/wvyry6tCHL

[Blue chip @b1u3chip]

2020 Top Stories in Renal Cell Carcinoma: Management of Renal Cell Carcinoma: Overview of Changes in the Past Decade | PracticeUpdate https://t.co/K2g0JEPlko

[Pavlos Msaouel @PavlosMsaouel]

1/6 Excited to share our review article on the management of metastatic rare #kidneycancer subtypes: https://t.co/onTuos186o @KidneyCancer @kcCURE @IKCCorg @kidneycan @renalmedullary @RmcAlliance

[Neeraj Agarwal, MD, FASCO @neerajaiims]

FDA expected to approve Moderna's Covid vaccine for use in the United States today👏👏. Which one to take ??Key difference in the side effects, characteristics of Moderna versus Pfizer vaccine & MOA.👇👇@OncoAlert

[ASCO @ASCO]

🎉 Congrats to our members who were elected to the ASCO Board of Directors and Nominating Cmte!
Dr. Mariana Chavez Mac Gregor of @MDAndersonNews
Dr. @teekayowo of @WinshipAtEmory
Dr. @RodriguezGIMD of @TheSTARTCenter
Dr. @DrMarkham of @UFMedicine
Dr. @n8pennell of @CleClinicMD

[Brian Rini, MD @brian_rini]

Why does PD-1-based therapy have superior outcomes in RCC? To me the clinical data are clear. All PD-1-based trials positive for OS, all PD-L1-based trials are negative. Summary data for IO/TKI trials here:

[BioStock @BioStock_SWE]

Immunicum erhåller Fast Track Designation från FDA för ilixadencel för behandling av GIST https://t.co/9pkdrdGeZ0 #BioStockSwe #LifeSciences @Immunicum

[Brian Rini, MD @brian_rini]

Updated summary tables for the major RCC front-line trials incorporating @AlbigesL recent 48 month Ipi/nivo data plus IMDC subset data. Len/Pembro is the only missing piece..

[gilberto lopes @GlopesMd]

Very promising results from Pfizer today. #COVID19nCANCER @COVID19nCCC #COVID19
https://t.co/DzPrMmZudp

[UT MD Anderson @UTMDAnderson]

What is T cell therapy? Watch to learn how this type of #immunotherapy works. #SITC2020 #EndCancer

[UT MD Anderson @UTMDAnderson]

“With immunotherapy, we are trying to harness or reinvigorate the immune system so that it recognizes and attacks the cancer,” says our Dr. Aung Naing: https://t.co/RDf3U8hlDH @ANaingMD #immunotherapy #EndCancer

[Immunovia @immunovia]

Immunovia Provides Complementary Details on the IMMray™ PanCan-d Verification Study. For complete press release: https://t.co/pwHbvJjvWF